Stay updated on Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page.

Latest updates to the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page
- Check3 days agoChange DetectedThe webpage’s footer revision version is updated from v3.5.2 to v3.5.3, reflecting a site release rather than a change to the trial record content.SummaryDifference0.1%

- Check10 days agoChange DetectedSite revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check46 days agoChange DetectedFooter now displays Revision: v3.4.3 and the previous Revision: v3.4.2 label was removed.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice, which are minor site maintenance updates that do not affect the study details or core content on this page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision to v3.4.1 (from v3.4.0).SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Doxorubicin in Sarcoma Clinical Trial page.